Patent ID: 9364565
Filing Date: 2016-06-14
CPC Classification: A61K,A61L,A61P,C12N

Claim Text:
1. A therapeutic system for treating a disease in a patient, the system comprising at least the following components to be separately administered to a patient in need thereof: (i) genetically altered mammalian endothelial progenitor cells, wherein mammalian endothelial progenitor cells are genetically altered by introducing exogenous nucleic acid encoding at least one exogenous unique cell membrane marker molecule not normally found in blood-circulating cells, the genetically altered mammalian endothelial progenitor cells further comprising at least one therapeutic gene product, wherein the exogenous unique cell membrane marker molecule is a truncated MHC class I molecule; and (ii) a medical device for implantation into the patient, the medical device comprising a biocompatible coating; said coating comprising a matrix comprising an antibody or fragment thereof, wherein said antibody or fragment thereof specifically binds said exogenous cell membrane marker molecule in vivo when said genetically altered mammalian endothelial progenitor cells are administered to the circulating blood of the patient, wherein said antibody or fragment thereof does not bind genetically unaltered, blood-circulating cells of the patient; wherein, in use of the therapeutic system, said separately administered genetically altered mammalian endothelial progenitor cells are captured from the circulating blood and bound to said medical device in situ, proliferate to form an endothelium, and secrete said at least one therapeutic gene product.